Coexpressed Catalase Protects Chimeric Antigen Receptor-Redirected T Cells as well as Bystander Cells from Oxidative Stress-Induced Loss of Antitumor Activity
- PMID: 26673145
- PMCID: PMC4705591
- DOI: 10.4049/jimmunol.1401710
Coexpressed Catalase Protects Chimeric Antigen Receptor-Redirected T Cells as well as Bystander Cells from Oxidative Stress-Induced Loss of Antitumor Activity
Abstract
Treatment of cancer patients by adoptive T cell therapy has yielded promising results. In solid tumors, however, T cells encounter a hostile environment, in particular with increased inflammatory activity as a hallmark of the tumor milieu that goes along with abundant reactive oxygen species (ROS) that substantially impair antitumor activity. We present a strategy to render antitumor T cells more resilient toward ROS by coexpressing catalase along with a tumor specific chimeric Ag receptor (CAR) to increase their antioxidative capacity by metabolizing H2O2. In fact, T cells engineered with a bicistronic vector that concurrently expresses catalase, along with the CAR coexpressing catalase (CAR-CAT), performed superior over CAR T cells as they showed increased levels of intracellular catalase and had a reduced oxidative state with less ROS accumulation in both the basal state and upon activation while maintaining their antitumor activity despite high H2O2 levels. Moreover, CAR-CAT T cells exerted a substantial bystander protection of nontransfected immune effector cells as measured by CD3ζ chain expression in bystander T cells even in the presence of high H2O2 concentrations. Bystander NK cells, otherwise ROS sensitive, efficiently eliminate their K562 target cells under H2O2-induced oxidative stress when admixed with CAR-CAT T cells. This approach represents a novel means for protecting tumor-infiltrating cells from tumor-associated oxidative stress-mediated repression.
Copyright © 2016 by The American Association of Immunologists, Inc.
Figures
Similar articles
-
Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor.Immunotherapy. 2013 Jun;5(6):577-90. doi: 10.2217/imt.13.37. Immunotherapy. 2013. PMID: 23725282
-
Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer.PLoS One. 2018 Jun 6;13(6):e0198347. doi: 10.1371/journal.pone.0198347. eCollection 2018. PLoS One. 2018. PMID: 29874279 Free PMC article.
-
Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response.Gene Ther. 2010 Oct;17(10):1206-13. doi: 10.1038/gt.2010.91. Epub 2010 Jun 17. Gene Ther. 2010. PMID: 20555360
-
Targeted immunotherapy of cancer with CAR T cells: achievements and challenges.Cancer Immunol Immunother. 2012 Jul;61(7):953-62. doi: 10.1007/s00262-012-1254-0. Epub 2012 Apr 22. Cancer Immunol Immunother. 2012. PMID: 22527245 Review.
-
Adoptive T-cell therapy of B-cell malignancies: conventional and physiological chimeric antigen receptors.Cancer Lett. 2012 Mar;316(1):1-5. doi: 10.1016/j.canlet.2011.10.027. Epub 2011 Oct 29. Cancer Lett. 2012. PMID: 22099879 Review.
Cited by
-
Chimeric Antigen Receptor T Cell Therapy for Hepatocellular Carcinoma: Where Do We Stand?Int J Mol Sci. 2024 Feb 23;25(5):2631. doi: 10.3390/ijms25052631. Int J Mol Sci. 2024. PMID: 38473878 Free PMC article. Review.
-
CARs are sharpening their weapons.J Immunother Cancer. 2024 Jan 31;12(1):e008275. doi: 10.1136/jitc-2023-008275. J Immunother Cancer. 2024. PMID: 38296592 Free PMC article. No abstract available.
-
Evolving CAR-T-Cell Therapy for Cancer Treatment: From Scientific Discovery to Cures.Cancers (Basel). 2023 Dec 20;16(1):39. doi: 10.3390/cancers16010039. Cancers (Basel). 2023. PMID: 38201467 Free PMC article. Review.
-
The role of ROS in tumor infiltrating immune cells and cancer immunotherapy.Metabolism. 2024 Feb;151:155747. doi: 10.1016/j.metabol.2023.155747. Epub 2023 Nov 30. Metabolism. 2024. PMID: 38042522 Review.
-
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn.Nat Rev Clin Oncol. 2024 Jan;21(1):47-66. doi: 10.1038/s41571-023-00832-4. Epub 2023 Oct 30. Nat Rev Clin Oncol. 2024. PMID: 37904019 Review.
References
-
- Fridman W.-H., Pagès F., Sautès-Fridman C., Galon J. 2012. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12: 298–306. - PubMed
-
- Büning H., Uckert W., Cichutek K., Hawkins R. E., Abken H. 2010. Do CARs need a driver’s license? Adoptive cell therapy with chimeric antigen receptor-redirected T cells has caused serious adverse events. Hum. Gene Ther. 21: 1039–1042. - PubMed
-
- Rosenberg S. A., Yang J. C., Sherry R. M., Kammula U. S., Hughes M. S., Phan G. Q., Citrin D. E., Restifo N. P., Robbins P. F., Wunderlich J. R., et al. 2011. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17: 4550–4557. - PMC - PubMed
-
- Scott A. M., Wolchok J. D., Old L. J. 2012. Antibody therapy of cancer. Nat. Rev. Cancer 12: 278–287. - PubMed
-
- Hiraki A., Kaneshige T., Kiura K., Ueoka H., Yamane H., Tanaka M., Harada M. 1999. Loss of HLA haplotype in lung cancer cell lines: implications for immunosurveillance of altered HLA class I/II phenotypes in lung cancer. Clin. Cancer Res. 5: 933–936. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
